Neurelis
Neurelis is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for epilepsy and the broader central nervous system (CNS) market. Founded in 2007 and based in Encinitas, California, Neurelis aims to address unmet medical needs through a differentiated approach that leverages novel technologies. The company's platform enhances drug delivery and therapeutic benefits across a variety of molecules, including therapeutic proteins, peptides, and small and large non-peptide molecules. By applying its expertise in neuroscience, Neurelis seeks to improve patient care and optimize treatment outcomes for individuals with epilepsy and other CNS disorders.
Aegis Therapeutics
Acquisition in 2018
Aegis Therapeutics is a San Diego-based drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through strategic partnerships. Intravail drug delivery technology enables the non-invasive, enhanced delivery of a broad range of protein, peptide and non-peptide drugs (up to 30,000 daltons in size) that can currently only be administered by injection. Intravail can be utilized via the oral, buccal, dermal, and intranasal administration routes of drug administration.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.